REVIEW PAPER
Reverse transcriptase inhibition: a way to defeat HIV
1
Department of Chemistry, Uttarakhand Technical University, India
2
Department of Chemistry, Graphic Era Deemed to be University, Dehradun, Uttarakhand, India
Submission date: 2021-03-30
Final revision date: 2021-05-22
Acceptance date: 2021-05-23
Publication date: 2022-01-15
HIV & AIDS Review 2022;21(1):3-9
KEYWORDS
human immunodeficiency virus (HIV)acquired immunodeficiency syndrome (AIDS)reverse transcriptase inhibitors (RTIs)
TOPICS
ABSTRACT
Human immunodeficiency virus (HIV) induces disease in humans that is known as AIDS (acquired immunodeficiency syndrome). First AIDS cases were registered in 1981, and later, types of HIV infection, such as HIV-1 and HIV-2 were identified. HIV belongs to class of retroviruses, known as ‘lentiviruses’ and ‘slow’ viruses. A literature assessment was conducted through several reliable national and international journals as well as books and monographs, to investigate reverse transcriptase inhibitor (RI) from human immunodeficiency virus type 1 (HIV-1). Reverse transcriptase inhibitor limits the reverse transcriptase activity, which is considered the key enzyme of retroviral multiplication process, and eventually prevents infection and progression of retroviruses. In the current paper, more than twenty-five drugs were presented, which are used for management/treatment of AIDS. The aim of the present review was to summarize the latest update on reverse transcriptase inhibition. Lately, significant advancement has been observed on the growth of HIV-drugs targeting reverse transcriptase enzyme. There is a continuous increase in various compounds with anti-HIV activity and isolated from natural sources. The present review provided a selection of publications concerning the topic. Salient features of reverse transcriptase inhibitors (both NRTIs and NNRTI's) and possibility for development of new chemical entity were presented.
REFERENCES (53)
1.
Barré-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 220: 868-871.
2.
Gallo RC, Salahuddin SZ, Popovic M, Shearer GM, Kaplan M, Haynes BF. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 1984; 224: 500-503.
3.
Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz, TA. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992; 256: 1783-1790.
4.
Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism and disease. Annu Rev Immunol 1999; 17: 657-700.
5.
Chiu IM, Yaniv A, Dahlberg JE, et al. Nucleotide sequence evidence for relationship of AIDS retrovirus to lentiviruses. Nature 1985; 317: 366-368.
6.
Smith J, Daniel R. Following the path of the virus: the exploitation of host DNA repair mechanisms by retroviruses. ACS Chem Biol 2006; 1: 217-226.
7.
Zheng YH, Lovsin N, Peterlin BM. Newly identified host factors modulate HIV replication. Immunol Lett 2005; 97: 225-234.
8.
Potter SJ, Lacabaratz C, Lambotte O, Perez-Patrigeon S, Vingert B, Sinet M. Preserved central memory and activated effector memory CD4 T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study. J Virol 2007; 81: 13904-13905.
9.
Giorgi J, Hultin L, McKeating J, Johnson T, Owens B, Jacobson L. Shorter survival in advanced human immunodefciency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999; 179: 859-870.
10.
Blankson J, Persaud D, Siliciano R. The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med 2002; 53: 557-593.
11.
Carr A, Cooper, DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356: 1423-1430.
12.
Liu S, Abbondanzieri EA, Rausch JW, Le Grice SF, Zhuang X. Slide into action: dynamic shuttling of HIV reverse transcriptase on nucleic acid substrates. Science 2008; 322: 1092-1097.
13.
Abbondanzieri EA, Bokinsky G, Rausch JW, Zhang JX, Le Grice SF, Zhuang X. Dynamic binding orientations direct activity of HIV reverse transcriptase. Nature 2008; 453: 184.
14.
Ghosh M, Jacques PS, Rodgers DW, Ottman M, Darlix JL, Le Grice SF. Alterations to the primer grip of p66 HIV-1 reverse transcriptase and their consequences for template-primer utilization. Biochemistry 1996; 35: 8553-8562.
15.
Thomas JA, Gorelick RJ. Nucleocapsid protein function in early infection processes. Virus Res 2008; 134: 39-63.
16.
DE Clercq E. Novel compounds in preclinical/early clinical development for the treatment of HIV infection. Rev Med Virol 2000; 10: 255.
17.
DE Clercq E. Antiviral drug discovery and development: where chemistry meets with biomedicine. Antiviral Res 2005; 67: 56-75.
18.
De Clercq E. The discovery of antiviral agents: ten different compounds, ten different stories. Med Res Rev 2008; 28: 929-953.
19.
Broder S, Gallo RC. Apathogenic retrovirus (HTLV-III) linked to AIDS. N Engl J Med 1984; 311: 1292-1297.
20.
Martins S, Ramos MJ, Fernandes PA. The current status of the NNRTI family of antiretrovirals used in the HAART regime against HIV infection. Curr Med Chem 2008; 15: 1083-1095.
21.
Tsibris AM Hirsch MS. Antiretroviral therapy in the clinic. J Virol 2010; 84: 5458-5464.
22.
Christopher AK, William L. Nucleoside reverse transcriptase inhibitor toxicity and mitochondrial DNA. Exp Opin Drug Metab Toxicol 2010; 6: 1493-1504.
23.
Mitsuya H, Weinhold KJ, Furman PA, St Clair MH, Lehrman SN, Gallo RC. 30-Azido-30-deoxythymidine (BW A509U): An antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A 1985; 82: 7096-7100.
24.
Mitsuya H, Popovic M, Yarchoan R, Matsushita S, Gallo RC, Broder S. Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLVIII. Science 1984; 226: 172-174.
25.
Mitsuya H, Broder S. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 20, 30 dideoxy nucleosides. Proc Natl Acad Sci U S A 1986; 83: 1911-1915.
26.
Cihlar T, Ray AS. Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. Antiviral Res 2010; 85: 39-58.
27.
Schinazi RF, Lloyd RM, Nguyen MH, Cannon DL, McMillan A, Ilksoy N. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother 1993; 37: 875-881.
28.
Sarafianos SG, Das K, Clark AD, Ding J, Boyer PL, Hughes SH. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with β-branched amino acids. Proc Natl Acad Sci 1999; 96: 10027-10032.
29.
Arion D, Kaushik N, McCormick S, Borkow G, Parniak MA. Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): Increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 1998; 37: 15908-15917.
30.
Farzad F, Thompson DW, Kelly CA, Meyer GJ. Competitive intermolecular energy transfer and electron injection at sensitized semiconductor interfaces. J Am Chem Soc 1999; 121: 5577-5578.
31.
Arts EJ, Hazuda DJ. HIV-1 antiretroviral drug therapy. Cold Spring Harbor Perspect Med 2012; 2: a007161.
32.
Baba M, Pauwels R, Herdewijn P, De Clercq E, Desmyter J, Vandeputte M. Both 20, 30-dideoxythymidine and its 20, 30-unsaturated derivative (20, 30-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro. Biochem Biophys Res Commun 1987; 142: 128-134.
33.
Hamamoto Y, Nakashima H, Matsui T, Matsuda A, Ueda T, Yamamoto N. Inhibitory effect of 2’, 3’-didehydro-2’, 3’-dideoxynucleosides on infectivity, cytopathic effects, and replication of human immunodeficiency virus. Antimicrob Agents Chemother 1987; 31: 907-910.
34.
Tai-Shun L, Schinazi RF, Prusoff WH. Potent and selective in vitro activity of 3’-deoxythymidin-2’-ene (3’-deoxy-2’,3’-didehydrothymidine) against human immunodeficiency virus. Biochem Pharmacol 1987; 36: 2713-2718.
35.
Soudeyns H, Yao XI, Gao Q, et al. Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 20-deoxy-30-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog. Antimicrob Agents Chemother 1991; 35: 1386-1390.
36.
Schinazi RF, McMillan A, Cannon D, Mathis R, Lloyd RM, Peck A. Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob Agents Chemother 1992; 36: 2423-2431.
37.
Daluge SM, Good SS, Faletto MB, Miller WH, St Clair, MH, Boone LR. 1592U89, a novel carbocyclic nucleoside analog with potent, selective antihuman immunodeficiency virus activity. Antimicrob Agents Chemother 1997; 41: 1082-1093.
38.
Farrokhi M, Gholami M, Mohraz M, McFarland W, Baesi K, Abbasian L. HIV drug resistance among naïve HIV-infected patients in Iran. J Res Med Sci 2019; 24: 31.
39.
Furman PA, Fyfe JA, St Clair MH, Weinhold K, Rideout JL, Freeman GA. Phosphorylation of 30-azido-30-deoxythymidine and selective interaction of the 50-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A 1986; 83: 8333-8337.
40.
Branson BM, Handsfield HH, Lampe MA, et al. Centers for Disease Control and Prevention (CDC).Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 2006; 55 (RR-14): 1-17.
41.
Lee S, Wood O, Tang S, et al. Detection of emerging HIV variants in blood donors from urban areas of Cameroon. AIDS Res Hum Retroviruses 2007; 23: 1262-1267.
42.
Greenwald JL, Burstein GR, Pincus J, Branson B. A rapid review of rapid HIV antibody tests. Curr Infect Dis Rep 2006; 8: 125-131.
43.
De Béthune MP. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009). Antiviral Res 2010; 85: 75-90.
44.
Balzarini J, De Clercq E. Biochemical pharmacology of nucleoside analogs active against HIV. In: Broder S, Merigan TC, Bolognesi D (eds.). Textbook of AIDS Medicine. Baltimore, Md.: Williams & Wilkins; 1994; 751-772.
45.
Jochmans D, Vingerhoets J, Arnoult E, Geeraert L, Guillemont J. Antiviral Research: Strategies in Antiviral Drug Discovery. Chapter 3: Human immunodeficiency virus type 1 non-nucleoside reverse transcriptase inhibitors. Washington: ASM Press; 2009; 33-50.
46.
Sluis-Cremer N, Temiz NA, Bahar I. Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding. Curr HIV Res 2004; 2: 323-332.
47.
Balzarini J. Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1. Curr Top Med Chem 2004; 4: 921-944.
48.
Podzamczer D, Fumero E. The role of nevirapine in the treatment of HIV-1 disease. Exp Opin Pharmacother 2001; 2: 2065-2078.
49.
Seetaha S, Hannongbua S, Rattanasrisomporn J, Choowongkomon K. Novel peptides with HIV‐1 reverse transcriptase inhibitory activity derived from the fruits of Quercus infectoria. Chem Biol Drug Design 2021; 97: 157-166.
50.
Benso B, Rosalen PL, Pasetto S, Marquezin MC, Freitas-Blanco V, Murata RM. Malva sylvestris derivatives as inhibitors of HIV-1 BaL infection. Natural Product Research 2021; 135: 1064-1069.
51.
Rimsky LT, Azijn H, Tirry I, et al. In vitro resistance profile of TMC278, a next generation NNRTI: evidence of a higher genetic barrier and a more robust resistance profile than first generation NNRTIs. Antiviral Ther 2009.
52.
Moyle G, Boffito M, Manhard K, Sheedy B, Hingorani V, Yeh, LT. Antiviral activity of RDEA806, a novel HIV non-nucleoside reverse transcriptase inhibitor, in treatment of näive HIV patients. In: XVIIth IAS Conference, Mexico City 2008.
53.
Zala C, Murphy R, Zhou XJ, et al. IDX899, a novel HIV-1 NNRTI with high barrier to resistance, provides suppression of HIV viral load in treatment-naïve HIV-1-infected subjects. In: XVIIth International AIDS Conference, Mexico City 2008.
Share
RELATED ARTICLE
| eISSN: | 1732-2707 |
| ISSN: | 1730-1270 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
